• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix completes $40M offering, updates product pipeline timetable

March 4, 2021 By Sean Whooley

pulmatrixPulmatrix (NSDQ:PULM) announced today that it completed an offering with gross proceeds of approximately $40 million.

Lexington, Mass.-based Pulmatrix said in a news release that it completed the registered direct offering to extend the company’s cash runway.

Now, the company has additional financing to help fully fund data readouts across its development pipeline, which includes a Phase 1b study for its PUR1800 therapeutic, a Phase 1/2 study for PUR3100 and a Phase 2b study for Pulmazole.

In the PUR1800 study, three of 15 patients have been dosed as Pulmatrix seeks to observe the safety, tolerability and exploratory biomarkers to demonstrate target engagement and anti-inflammatory effect in treating lung cancer. The company expects Phase 1b topline data in the fourth quarter of this year.

The company had a Type C meeting with the FDA to further the development of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis asthmatics. Pulmatrix dosed the first patient in its Phase 2 study for the drug in September 2019 and plans to initiate the Phase 2b study in the first quarter of 2022.

Finally, PUR3100 was used in a dog PK study as a dry powder, inhaled iSperse formulation of DHE, in which the company observed the iSperse formulation mitigating the manufacturing and device issues encountered with the MAP Pharmaceuticals inhaled formulation of DHE while maintaining similar exposure kinetics in treating acute migraine. Pulmatrix anticipates advancing into investigational new drug enabling toxicology studies with a Phase 1/Phase 2 study starting in the first quarter of 2022.

“We are very excited to have three iSperse-enabled programs with potential to address significant unmet need in lung cancer, allergic bronchopulmonary aspergillosis and acute migraine,” Pulmatrix CEO Ted Raad said in the release.  “We have made significant advancements across every program and our now strengthened balance sheet leaves us well-positioned to execute across our diversified pipeline to key data readouts and get one step closer to bringing these important therapies to patients.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup, Pharmaceuticals, Research & Development Tagged With: Pulmatrix Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS